33rd Conference of ENTIS
8th-10th September 2022

BERGAMO, ITALY
Poison Control Center and Teratology Information Service

CENTRO CONGRESSI “GIOVANNI XXIII”

With the collaboration of

www.asst-pg23.it
Wednesday, 7 September

16.00 – 18.30 Board, Scientific and Website Committee Meetings

Conference room 1) Sala Novelli
2) Sala Stampa
3) Sala Business

Thursday, 8 September

08.00 – 09.30 Registration

Conference room Sala Alabastro

TRAINING IN TERATOLOGY
Chair: Orna Diav-Citrin

09.30 – 09.55 The teratogenic risk of caffeine in pregnancy M. Gallo (20+5 min)
09.55 – 10.20 Risk communication and scientific misinformation A. Clavenna (20+5min)
10.20 – 10.45 Cobalt exposure due to metal-on-metal hip prosthesis in pregnancy: toxicological risks A. Giampreti (20+5min)

10.45 – 11.00 Coffee Break Catering room Sala Bianca

TRAINING IN TERATOLOGY
Chair: Wolfgang Paulus & Maria Ellfolk

11.00 – 11.25 Hyperpyrexia as a major teratogen: COVID-19 vaccine implications S. Običan (20+5 min)
11.25 – 12.00 Free Discussions

12.00 – 13.30 Lunch Catering room Roof garden

ENTIS BUSINESS MEETING
Chair: Orna Diav-Citrin & Sally Stephens

13.30 – 15.30 ENTIS business meeting

15.30 – 16.00 Coffee Break Catering room Sala Bianca

MEETING OPENING

16.00 – 16.05 Welcome greetings from ENTIS - Official opening Orna Diav-Citrin
16.05 – 16.10 Welcome greetings from Bergamo TIS G. Bacis

SESSION 1 COVID-19 IN PREGNANCY
Chair: Marco De Santis & Yusuf Cem Kaplan

16.10 – 16.35 Pregnancy and COVID-19 L. Patanè (20+5 min)
16.35 – 17.00 COVID-19 vaccines and pregnancy S. Pirola (20+5 min)
17.00 – 17.25 Breastfeeding and COVID-19 R. Davanzo (20+5 min)
17.25 – 18.00 Vaccine uptake among pregnant women: lessons learned and future challenges B. Cleary (20 min + 15 discussion)

End of the first day meeting
SESSION 2A  CURRENT CONTROVERSIAL ISSUES ON DRUGS IN PREGNANCY
Chair: Jorgos Eleftheriou & Per Damkier

09.00 – 09.25 Introduction to current controversies in teratology: some myths revisited O. Diav-Citrin (20+5 min)
09.25 – 09.50 Acetaminophen use in pregnancy and ASD & ADHD Y.C. Kaplan (20+10 min)
09.50 – 10.15 Reprotoxic effects of drugs: differences and similarities between clinical and regulatory approaches R. Butera (20+5"
10.15 – 10.40 The pathophysiology of neonatal abstinence syndrome due to SSRI C. Chambers (20+5 min)

10.40 – 11.15 Coffee Break, networking and Poster visit Catering room Sala Bianca & Sala Stucchi

SESSION 2B  CURRENT CONTROVERSIAL ISSUES ON DRUGS IN PREGNANCY
Chair: Thierry Vial & Mehmet Zafer Gören

11.15 – 11.40 Ondansetron in pregnancy P. Damkier (20+5 min)
11.40 – 12.05 New pharmacological treatment of opiate addiction in pregnant women L. Somaini (20+5 min)
12.05 – 12.30 NSAID treatment in pregnancy: Risk estimation in the 1st and 2nd/3rd trimester K. Dathe (20+5 min)
12.30 – 13.15 Panel Discussion on the role of ENTIS in the public debate on controversies of drugs in pregnancy (Panel: Board and SC Members, 45 min)

13.15 – 14.30 Lunch, networking Catering room Roof garden

SESSION 2C  CURRENT CONTROVERSIAL ISSUES ON DRUGS IN PREGNANCY
Chair: Herbert Juch & Lucie Heringová

14.30 – 15.00 Disease activity assessment of rheumatic diseases and treatment in pregnancy S. Breda, V. Ramoni (20+5 min)

15.00 – 16.30 FREE COMMUNICATIONS (10+5 min discussion)
15.00 – 15.15 Development and validation of a machine-learning algorithm to predict the relevance of scientific articles in teratology Loes C de Vries
15.15 – 15.30 Potential Sources of Bias in the Analysis of COVID-19 Vaccine Safety during Pregnancy: How the Embryotox study plans to avoid them by design and analysis methods Regina Stegherr
15.30 – 15.45 COVID-19 mRNA vaccine in pregnancy: results of the Swiss COVI-PREG registry Guillaume Favre
15.45 – 16.00 An overview of the UK COVID-19 Antivirals Pregnancy Registry Jonathan Richardson
16.00 – 16.15 Risk of Miscarriage Following Exposure to NSAIDs During Early Pregnancy: A Systematic Review and Meta-Analysis Maya Berlin
16.15 – 16.30 Sildenafil and bosentan quantification in human milk: a case report from the ConcePTION project Michael Ceulemans

FRIDAY NIGHT: ENTIS DINNER
20.00 – 23.30 Taverna dnnd
SESSION 3  PSYCHOTROPIC DRUGS IN PREGNANCY AND BREASTFEEDING

Chair: Mattithahu Berkovitch & Stephanie Padberg

09.00 – 09.25 Antipsychotics in pregnancy: balancing between risks of untreated illness and risks of drug-related adverse effects U. Albert (20+5min)

09.25 – 09.50 Long-Acting Injectable Antipsychotics use in pregnancy. The Papa Giovanni XXIII Hospital experience E. Bondi, C. Palumbo (20+5min)

09.50 – 10.15 The pharmacokinetics of antidepressant drugs in breastfeeding D. Cattaneo (20+5min)

10.15 – 10.40 Neonatal abstinence syndrome: laboratory findings P. Papa (20+5min)

10.40 – 11.00 Panel Discussion

11.00 – 12.00 Coffee Break and Poster visit Catering room Sala Bianca & Sala Stucchi

SESSION 4  FREE COMMUNICATIONS AND DEBATES

Chair: Ursula Winterfeld & Matteo Cassina

12.00 – 13.00 FREE COMMUNICATIONS (10+5 min discussion)

12.00 – 12.15 Anti-seizure medication use during pregnancy, trends over time and individual treatment pattern: An Evaluation of the German Embryotox Cohort. Maria Hoeltzenbein

12.15 – 12.30 Neonatal morbidity after fetal exposure to antipsychotics - a national register-based study. Aessi Heinonen

12.30 – 12.45 Pregnancy outcome following first-trimester exposure to mirtazapine: an observational comparative cohort study. S. Shweiki


13.00 – 13.30 Brief status from the ConCEPTION project

13.30 CLOSURE

CENTRO CONGRESSI “GIOVANNI XXIII”
POSTER PRESENTATIONS

1. Development of a process for collaborative management of the IMI ConCePTION Knowledge Bank - Alison Olivier
2. Which elements do we include, and how do we present them, in answers on use of medications during breastfeeding? A descriptive pilot study - Tina Bakkebo
3. Use of Prescribed Drugs to Treat Chronic Diseases during Pregnancy in Outpatient Care in Switzerland between 2014 and 2018: Descriptive Analysis of Swiss Health Care Claims Data - Eva Gerbier
4. Mental health of pregnant and postpartum women during the third wave of the Covid-19 pandemic. A European cross-sectional study - Fatima Tauqeer
5. Open issues in management of carbon monoxide poisoning in pregnancy: practical suggestions - Georgios Eleftheriou
6. Can topical NSAIDs be used by pregnant women in the third trimester? - Gro C Havnen
7. Why did the Magdalena study- an RCT on the effects on infants born to women with treatment of depression in pregnant women- fail? - Katarina Wide
8. Neonatal outcome and adherence to drug therapy in bronchial asthma in pregnancy - Cecilia Lanzi
9. Feasibility assessment and validation of the prototype of the Belgian data registration system on medication use during pregnancy and mother-infant outcomes (BELpREG) - Laure Sillis
10. Experiences and perspectives of pharmaceutical industry towards the monitoring of medication safety during pregnancy: a qualitative analysis on a pan-European level - Laure Sillis
11. Information needs and preferences of pharmacy staff regarding safe compounding of medicines during pregnancy and lactation: results from a cross-sectional survey in Belgium - Laure Sillis
12. Psychomotor development of children exposed to Ondansetron during pregnancy: a prospective cohort study - Maya Berlin
13. Neurodevelopmental outcome of children exposed to Selective Serotonin Reuptake inhibitors (SSRI's) or Attention Deficit Hyperactivity Disorder (ADHD) stimulant medications during pregnancy - Maya Berlin
15. Evaluation Of Pregnancy Using Mirabegron In Terms Of Teratogenity - Mine Kadioglu Duman
17. Outcomes of Olanzapine Exposure in Pregnancy - Mine Kadioglu Duman
19. Queries on medication use during pregnancy: an analysis of data from the Swiss Teratogen Information Service - Ursula Winterfeld
20. Renal pathologies and mesalazine use in pregnancy - M. Zafer Goren
21. Bilateral renal agenesis following in utero first trimester exposure to gadobutrol - Ksenia Zagorodnikova
22. Evolution of the national guidelines on the medicines used to treat COVID-19 in pregnancy: a historical review - Emeline Maisonneuve
23. Agomelatine for the treatment of depressive episodes - preliminary data on the use in pregnancy - Wolfgang Paulus
SPEAKERS
Albert Umberto, University of Trieste
Breda Silvia, HPG23, Bergamo
Butera Raffaella, Toxicon, Pavia
Caplan Yusuf Cem, Ind. researcher, Berlin
Cattaneo Dario, Hospital Sacco, Milan
Chambers Christina, OTIS, USA
Clavenna Antonio, Mario Negri, Milan
Cleary Brian, Rotunda Hospital, Dublin
Damkier Per, Odense, Denmark
Dathe Katarina, Berlin, Germany
Davanzo Riccardo, Hospital Burlo, Trieste
Dian Citrin Orna, Jerusalem, Israel
Gallo Mariapina, HPG23, Bergamo
Giampreti Andrea, HPG23, Bergamo
Običan Sarah, OTIS, USA
Palamo Claudia, HPG23, Bergamo
Papa Pietro, San Matteo, Pavia, Italy
Patanè Luisa, HPG23, Bergamo
Pirola Serena, HPG23, Bergamo
Ramoni Veronique, San Matteo, Pavia
Somaini Lorenzo, SERD, Biella

CONFERENCE LOCATION
Centro Congressi Giovanni XXIII
Viale Papa Giovanni XXIII, 106
24121 Bergamo

REGISTRATION FOR THE CONGRESS
Information is available on the ENTIS website

POSTERS
Information on poster size and orientation is available on the ENTIS website

DEADLINE DATES
Registration opens 1 April, 2022

Registration
Registration at special rates
1 April - 31 May 2022 (€ 300)

Registration at normal rates
1 June - 31 July 2022 (€ 355)

Registration 1 August to 25 August, the Congress Center can accept any registration, asking before by email and paying by bank transfer

Registration on congress site
7-9 September 2022 (€ 400)

One day Registration
1 April - 9 September 2022 (€ 150)

ENTIS DINNER
Included for registered participants
Accompanying person and one day registration (€ 65)

CONTACT
Centro Congressi Giovanni XXIII
Miss Chiara Vitali
Tel. +39 035 236435
Fax +39 035 236474
e-mail eventi@centrocongressibergamo.com

In collaboration with
EUROPEAN NETWORK OF TERATOLOGY
INFORMATION SERVICES

ITALIAN SOCIETY OF PSYCHIATRY
ITALIAN SOCIETY OF GYNECOLOGY AND OBSTETRICS
ITALIAN SOCIETY OF TOXICOLOGY
ITALIAN SOCIETY OF NEONATOLOGY